International consensus for the treatment of autoimmune pancreatitis

Kazuichi Okazaki; Suresh T. Chari; Luca Frulloni; Markus M. Lerch; Terumi Kamisawa; Shigeyuki Kawa; Myung Hwan Kim; Philippe Lévy; Atsushi Masamune; George Webster; Tooru Shimosegawa

doi:10.1016/j.pan.2016.12.003

International consensus for the treatment of autoimmune pancreatitis

Kazuichi Okazaki, Suresh T. Chari, Luca Frulloni, Markus M. Lerch, Terumi Kamisawa, Shigeyuki Kawa, Myung Hwan Kim, Philippe Lévy, Atsushi Masamune, George Webster, Tooru Shimosegawa

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Background and aims The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

Original language	English (US)
Pages (from-to)	1-6
Number of pages	6
Journal	Pancreatology
Volume	17
Issue number	1
DOIs	https://doi.org/10.1016/j.pan.2016.12.003
State	Published - Jan 1 2017

Keywords

Autoimmune pancreatitis
Immunomodulatory
Rituximab
Steroid
Treatment

ASJC Scopus subject areas

Endocrinology
Endocrinology, Diabetes and Metabolism
Hepatology

Access to Document

10.1016/j.pan.2016.12.003

Cite this

@article{4fd85803d3df4ae3b2dcb5252c6eaef1,

title = "International consensus for the treatment of autoimmune pancreatitis",

abstract = "Background and aims The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.",

keywords = "Autoimmune pancreatitis, Immunomodulatory, Rituximab, Steroid, Treatment",

author = "Kazuichi Okazaki and Chari, {Suresh T.} and Luca Frulloni and Lerch, {Markus M.} and Terumi Kamisawa and Shigeyuki Kawa and Kim, {Myung Hwan} and Philippe L{\'e}vy and Atsushi Masamune and George Webster and Tooru Shimosegawa",

note = "Publisher Copyright: {\textcopyright} 2016 IAP and EPC",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.pan.2016.12.003",

language = "English (US)",

volume = "17",

pages = "1--6",

journal = "Pancreatology",

issn = "1424-3903",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - International consensus for the treatment of autoimmune pancreatitis

AU - Okazaki, Kazuichi

AU - Chari, Suresh T.

AU - Frulloni, Luca

AU - Lerch, Markus M.

AU - Kamisawa, Terumi

AU - Kawa, Shigeyuki

AU - Kim, Myung Hwan

AU - Lévy, Philippe

AU - Masamune, Atsushi

AU - Webster, George

AU - Shimosegawa, Tooru

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background and aims The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

AB - Background and aims The International Consensus Diagnostic Criteria (ICDC) for AIP has proposed two distinctive type of AIP, type 1 and type 2, and enabled us first to differentiate two types of AIP each other. By initial steroid treatment for induction of remission, remission can be successfully induced in almost all subjects with type 1 and type 2 AIP. As relapse rate in type 1 AIP is significantly higher than in type 2 AIP, there has been ongoing debate on how to treat effectively relapse of type 1 AIP. Methods By a modified Delphi approach, a panel of international experts has proposed an international consensus on the treatment of AIP after intense discussion and deliberation during an international consensus symposium of the International Association of Pancreatology (IAP) 2016. Results Individual statements for nine clinical questions with recommendation levels and the therapeutic strategy have been proposed. Conclusion The recommendations are based on the available evidence, and eastern and western experts' opinions to find standard treatment of AIP worldwide. These recommendations can be tailored according to the local expertise and context in the management of individual patients.

KW - Autoimmune pancreatitis

KW - Immunomodulatory

KW - Rituximab

KW - Steroid

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85008152751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008152751&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2016.12.003

DO - 10.1016/j.pan.2016.12.003

M3 - Article

C2 - 28027896

AN - SCOPUS:85008152751

SN - 1424-3903

VL - 17

SP - 1

EP - 6

JO - Pancreatology

JF - Pancreatology

IS - 1

ER -

International consensus for the treatment of autoimmune pancreatitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this